Albireo Pharma Inc (NASDAQ:ALBO) has earned an average recommendation of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $60.33.
A number of research firms have recently issued reports on ALBO. William Blair reiterated a “buy” rating on shares of Albireo Pharma in a research note on Monday, July 15th. HC Wainwright reissued a “buy” rating and issued a $62.00 price objective on shares of Albireo Pharma in a research note on Sunday, August 11th. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Zacks Investment Research lowered Albireo Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. Finally, BidaskClub raised Albireo Pharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 21st.
Shares of ALBO stock traded up $0.38 on Thursday, hitting $25.70. The stock had a trading volume of 25,654 shares, compared to its average volume of 49,851. The business has a 50 day moving average price of $24.87 and a 200 day moving average price of $30.24. The company has a market cap of $320.43 million, a PE ratio of -6.52 and a beta of 1.53. Albireo Pharma has a one year low of $19.10 and a one year high of $38.69.
Albireo Pharma (NASDAQ:ALBO) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.44) by $0.09. Albireo Pharma had a negative net margin of 2,403.88% and a negative return on equity of 51.74%. The company had revenue of $1.25 million for the quarter, compared to analysts’ expectations of $1.11 million. On average, research analysts predict that Albireo Pharma will post -5.91 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the business. Federated Investors Inc. PA lifted its position in shares of Albireo Pharma by 22.8% during the first quarter. Federated Investors Inc. PA now owns 719,595 shares of the biopharmaceutical company’s stock valued at $23,178,000 after buying an additional 133,449 shares during the last quarter. BlackRock Inc. raised its stake in shares of Albireo Pharma by 14.7% during the 2nd quarter. BlackRock Inc. now owns 658,767 shares of the biopharmaceutical company’s stock worth $21,239,000 after acquiring an additional 84,575 shares in the last quarter. Chicago Capital LLC raised its stake in shares of Albireo Pharma by 6.8% during the 2nd quarter. Chicago Capital LLC now owns 202,241 shares of the biopharmaceutical company’s stock worth $6,520,000 after acquiring an additional 12,833 shares in the last quarter. Man Group plc lifted its position in Albireo Pharma by 770.4% during the second quarter. Man Group plc now owns 189,500 shares of the biopharmaceutical company’s stock valued at $6,109,000 after acquiring an additional 167,729 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Albireo Pharma by 10.1% during the second quarter. Vanguard Group Inc. now owns 177,647 shares of the biopharmaceutical company’s stock valued at $5,727,000 after acquiring an additional 16,236 shares during the last quarter. Institutional investors and hedge funds own 73.02% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Recommended Story: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.